Mile High Peptides

🧠 Plot Twist: This One Isn’t a GLP-1 Agonist.
For the final day of MHP Metabolic Research Week, we’re stepping outside the GLP-1 pathway.
🔬 Tesofensine is fundamentally different from the GLP-1, GIP and glucagon receptor agonists we’ve explored this week.
Rather than acting as a GLP-1 receptor agonist, Tesofensine has been investigated for its effects on monoamine reuptake, involving signaling systems that include dopamine, norepinephrine and serotonin.
That gives researchers a very different mechanism to investigate.
🧬 GLP-focused research → receptor signaling
🧠 Tesofensine research → monoamine signaling
And that’s an important reminder: compounds discussed within the same broad area of metabolic research don’t necessarily work through the same biological pathway.
Different pathway. Different mechanism. Different research question.
🔬 Day 7 of 7 | MHP Metabolic Research Week
Missed one of this week’s topics? We explored GLP-1 vs. GIP vs. glucagon, Tirzepatide, Retatrutide, Survodutide, Mazdutide, Orforglipron and Tesofensine.
📚 The series may be ending, but the research doesn’t.
www.milehighpeptides.com/education-hub
For laboratory research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

🔬 Does a GLP-1 Receptor Agonist Have to Be a Peptide?
No—and that’s what makes today’s research topic so interesting.
Throughout MHP Metabolic Research Week, we’ve explored several investigational compounds involving GLP-1 receptor signaling.
But Orforglipron is different.
🧬 Orforglipron is being investigated as a non-peptide, small-molecule GLP-1 receptor agonist.
That distinction gives researchers another approach for studying the same receptor family.
Think about the research question this way:
Peptide-based approach → GLP-1 receptor Small-molecule approach → GLP-1 receptor
🔬 Same receptor family. Different molecular approach.
Understanding that distinction is important because modern GLP-1 research isn’t limited to studying one type of molecular structure.
🧬 Day 6 of MHP Metabolic Research Week
Tomorrow we’re stepping outside the GLP pathway entirely with Tesofensine—and explaining why it still appears in metabolic research discussions.
📚 Curious about the science behind today’s emerging research compounds?
www.milehighpeptides.com/education-hub
For laboratory research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

🧬 Same Receptor Targets. Same Research Compound? Not Necessarily.
Yesterday we explored Survodutide, an investigational compound studied for dual GLP-1 + glucagon receptor agonism.
Today we’re looking at Mazdutide—another investigational compound involving those same two receptor families.
So why study both?
🔬 Sharing receptor targets doesn’t make two research compounds identical.
Researchers can investigate differences in areas such as molecular design, receptor activity and broader pharmacologic characteristics—even when compounds are designed around similar signaling pathways.
That distinction is important when looking at emerging multi-receptor research:
Survodutide → GLP-1 + Glucagon Mazdutide → GLP-1 + Glucagon
Similar targets. Different investigational compounds.
And that’s where the research question becomes more interesting than simply counting receptors.
🧬 Day 5 of MHP Metabolic Research Week
Tomorrow we’re changing direction: Orforglipron. Does a GLP-1 receptor agonist even have to be a peptide?
📚 Compare the pathways and explore the research:
www.milehighpeptides.com/education-hub
For laboratory research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

🧬 GLP-1 + Glucagon: Why Are Researchers Studying These Two Pathways Together?

We’ve gone from one receptor… to two… to three.

Now let’s look at a different combination.
🔬 Survodutide is an investigational dual receptor agonist being studied for activity at both the GLP-1 and glucagon receptors.
What makes that interesting?

GLP-1 and glucagon participate in different aspects of metabolic signaling, so researchers are investigating what happens when these two receptor pathways are targeted together within a single compound.

And here’s an important distinction from Monday:
Tirzepatide: GIP + GLP-1 Survodutide: Glucagon + GLP-1
Both involve two receptor targets—but they’re not studying the same combination of pathways.

That difference is exactly what makes modern multi-receptor research so interesting.

🔬 Different combination. Different research question.

🧬 Day 4 of MHP Metabolic Research Week

Tomorrow: Mazdutide — another GLP-1 + glucagon research compound. So what makes studying multiple compounds targeting similar pathways valuable?

📚 Continue exploring the science:
www.milehighpeptides.com/education-hub
Educational content for research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

🔬 What Happens When Two Pathways Become Three?

Yesterday we explored dual-receptor research. Today, we’re adding a third pathway.

🧬 Retatrutide is an investigational triple receptor agonist designed to activate:
GLP-1 + GIP + Glucagon
Why is that scientifically interesting?

Instead of investigating one metabolic signaling pathway—or even two—researchers can examine what happens when three distinct receptor systems are engaged within the same investigational approach.

That makes Retatrutide an important subject in the evolving study of multi-receptor metabolic signaling and raises a bigger research question:

🔬 How does triple-receptor signaling differ from single- and dual-receptor approaches?

Three pathways. One fascinating research question.

🧬 Day 3 of MHP Metabolic Research Week
Tomorrow: Survodutide — why are researchers investigating GLP-1 + glucagon together?

📚 Explore the science and continue your research:
www.milehighpeptides.com/education-hub

Educational content for research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.

🔬 Why Target Two Receptors Instead of One?

Yesterday we looked at GLP-1, GIP and glucagon individually. Today, we’re looking at what happens when research brings two pathways together.

🧬 Tirzepatide is a dual GIP + GLP-1 receptor agonist that has become an important subject in metabolic research.
Rather than focusing exclusively on GLP-1 receptor signaling, tirzepatide provides researchers with a model for investigating how simultaneous GIP and GLP-1 receptor activity may influence interconnected metabolic pathways.
That’s what makes dual-receptor research so interesting: it’s not simply about adding another target—it’s about understanding how the signaling pathways interact.

Two receptors. One compound. A different research question.

🔬 Day 2 of MHP Metabolic Research Week

Tomorrow: Retatrutide — what changes when research moves from TWO receptor targets to THREE?

📚 Continue exploring the science at:
www.milehighpeptides.com/education-hub
Educational content for research purposes only. Not intended to diagnose, treat, cure, or prevent any disease.